Was thinking about the SARAH trial, and wondering if the data would increase the chances of public sector reimbursement in France. Being a public funding situation it will always be a big ask, but the data may well support HCC, especially the right hand source pts.
Trust the EU dudes are actively pursuing this in France.
I do hope that, if granted, it is not restricted by annual cap as in the UK.
Was thinking about the SARAH trial, and wondering if the data...
Add to My Watchlist
What is My Watchlist?